Literature DB >> 22926606

Akathisia and suicidal ideation in first-episode schizophrenia.

Florian Seemüller1, Rebecca Schennach, Andreas Mayr, Richard Musil, Markus Jäger, Wolfgang Maier, Stefan Klingenberg, Isabella Heuser, Joachim Klosterkötter, Markus Gastpar, Andrea Schmitt, Ralf Schlösser, Frank Schneider, Christian Ohmann, Ute Lewitzka, Wolfgang Gaebel, Hans-Jürgen Möller, Michael Riedel.   

Abstract

Patients with first-episode schizophrenia (FES) are known to be notably sensitive for developing extrapyramidal adverse effects, but the relation of akathisia and suicidal ideation has rarely been studied. The current report is an ongoing analysis of an 8-week double-blind randomized controlled multicenter trial in 289 FES, comparing risperidone and haloperidol. Assessments were conducted weekly and included the Hillside Akathisia Scale and 21-item Hamilton Depression Rating Scale ratings. Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol. The allocated treatment, anxiety, and nervousness had no influence. The present findings suggest a promoting effect of akathisia on suicidal ideation can not be ruled out in patients with FES.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926606     DOI: 10.1097/JCP.0b013e3182677958

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  10 in total

1.  Haloperidol discontinuation for people with schizophrenia.

Authors:  Adib Essali; Khaled Turkmani; Shaimaa Aboudamaah; Alaa AbouDamaah; Mohammad Reyad Diaa Aldeen; Mohamad Essam Marwa; Nawar AlMounayer
Journal:  Cochrane Database Syst Rev       Date:  2019-04-21

2.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

3.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

4.  Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.

Authors:  Bunta Yoshimura; Kojiro Sato; Shinji Sakamoto; Masaru Tsukahara; Yusaku Yoshimura; Ryuhei So
Journal:  Psychopharmacology (Berl)       Date:  2018-11-15       Impact factor: 4.530

Review 5.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

6.  The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Authors:  Tamara Pringsheim; David Gardner; Donald Addington; Davide Martino; Francesca Morgante; Lucia Ricciardi; Norman Poole; Gary Remington; Mark Edwards; Alan Carson; Thomas R E Barnes
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

Review 7.  The Incidence of Akathisia in the Treatment of Schizophrenia with Aripiprazole, Asenapine and Lurasidone: A Meta-Analysis.

Authors:  Jennifer E Thomas; Joshua Caballero; Catherine A Harrington
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 8.  The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review.

Authors:  Arturas Kalniunas; Ipsita Chakrabarti; Rakhee Mandalia; Jasna Munjiza; Sofia Pappa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-03       Impact factor: 2.570

Review 9.  The Importance of Suicide Risk Formulation in Schizophrenia.

Authors:  Isabella Berardelli; Elena Rogante; Salvatore Sarubbi; Denise Erbuto; David Lester; Maurizio Pompili
Journal:  Front Psychiatry       Date:  2021-12-16       Impact factor: 4.157

10.  Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression.

Authors:  Thomas M Penders; Salina Agarwal; Rachel Rohaidy
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-04       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.